DE10326189A1 - Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe - Google Patents
Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe Download PDFInfo
- Publication number
- DE10326189A1 DE10326189A1 DE10326189A DE10326189A DE10326189A1 DE 10326189 A1 DE10326189 A1 DE 10326189A1 DE 10326189 A DE10326189 A DE 10326189A DE 10326189 A DE10326189 A DE 10326189A DE 10326189 A1 DE10326189 A1 DE 10326189A1
- Authority
- DE
- Germany
- Prior art keywords
- bacteria
- cell
- gene
- microorganism
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title claims description 4
- 239000000969 carrier Substances 0.000 title description 2
- 241000894006 Bacteria Species 0.000 claims abstract description 67
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 244000005700 microbiome Species 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 4
- 239000013611 chromosomal DNA Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 239000013612 plasmid Substances 0.000 claims description 23
- 241000186781 Listeria Species 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 101150037081 aroA gene Proteins 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 101150059846 trpS gene Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 9
- 210000000172 cytosol Anatomy 0.000 claims description 9
- -1 aromatic amino acids Chemical class 0.000 claims description 8
- 101150004782 trpS2 gene Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000015271 coagulation Effects 0.000 claims description 4
- 238000005345 coagulation Methods 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 101150021185 FGF gene Proteins 0.000 claims description 3
- 102000053187 Glucuronidase Human genes 0.000 claims description 3
- 108010060309 Glucuronidase Proteins 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 3
- 102000004157 Hydrolases Human genes 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims description 3
- 108020005091 Replication Origin Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000035602 clotting Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 241000123765 Listeria phage A118 Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 102000043276 Oncogene Human genes 0.000 claims description 2
- 108700020796 Oncogene Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 210000001608 connective tissue cell Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 230000000770 proinflammatory effect Effects 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 231100000508 hormonal effect Toxicity 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 4
- 230000001018 virulence Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 9
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 241001167018 Aroa Species 0.000 description 7
- 241000186779 Listeria monocytogenes Species 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 5
- 101150100002 iap gene Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101150025117 IL3 gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000440393 Listeria monocytogenes EGD-e Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000240602 cacao Species 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150095218 der gene Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1092—3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10326189A DE10326189A1 (de) | 2003-06-06 | 2003-06-06 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
| DE112004001496T DE112004001496D2 (de) | 2003-06-06 | 2004-06-07 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
| PCT/DE2004/001180 WO2004108906A2 (fr) | 2003-06-06 | 2004-06-07 | Supports bacteriens pour sequences nucleotidiques codant des substances actives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10326189A DE10326189A1 (de) | 2003-06-06 | 2003-06-06 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10326189A1 true DE10326189A1 (de) | 2005-01-05 |
Family
ID=33494938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10326189A Withdrawn DE10326189A1 (de) | 2003-06-06 | 2003-06-06 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
| DE112004001496T Expired - Fee Related DE112004001496D2 (de) | 2003-06-06 | 2004-06-07 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE112004001496T Expired - Fee Related DE112004001496D2 (de) | 2003-06-06 | 2004-06-07 | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe |
Country Status (2)
| Country | Link |
|---|---|
| DE (2) | DE10326189A1 (fr) |
| WO (1) | WO2004108906A2 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| JP2002513287A (ja) * | 1997-04-18 | 2002-05-08 | ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー（ゲー ベー エフ） | サルモネラ株 |
| US6143551A (en) * | 1997-12-29 | 2000-11-07 | Schering Aktiengesellschaft | Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria |
-
2003
- 2003-06-06 DE DE10326189A patent/DE10326189A1/de not_active Withdrawn
-
2004
- 2004-06-07 WO PCT/DE2004/001180 patent/WO2004108906A2/fr active Application Filing
- 2004-06-07 DE DE112004001496T patent/DE112004001496D2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE112004001496D2 (de) | 2006-04-20 |
| WO2004108906A2 (fr) | 2004-12-16 |
| WO2004108906A3 (fr) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629576T2 (de) | Verfahren zur herstellung von rekombinanten plasmiden | |
| DE69433921T2 (de) | Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie | |
| DE60113851T2 (de) | Bakteriophage mit breitem wirtsspektrum | |
| JP6949184B2 (ja) | 治療的な使用のための、核酸送達のための治療用ファージおよび方法 | |
| US20190315642A1 (en) | Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome | |
| DE60031974T2 (de) | Abgeschwächte Mikroorganismen zur Behandlung von Infektionen | |
| JP3090270B2 (ja) | 生物学的封じ込め | |
| DD209476A5 (de) | Verfahren zur stabilisierung und selektierung von wirtszellen, die rekombinierende dna enthalten | |
| DE3308030C2 (de) | Tierische Interferone | |
| DE60319083T2 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin-entzug | |
| DE60315636T2 (de) | Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen | |
| CN110612349A (zh) | 新型铜绿假单胞菌噬菌体Pse-AEP-3及其用于抑制铜绿假单胞菌的增殖的用途 | |
| DE60107707T2 (de) | Mikroben mit einer transkriptionsabbrecher enthaltender dämpfender mutation | |
| DE60204317T2 (de) | Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen | |
| EP0775203B1 (fr) | Procede de therapie genique utilisant des vecteurs d'adn sans gene marqueur de selection | |
| DE69828414T2 (de) | Mukosale zytotoxische t-lymphozytenantwort | |
| EP1023453B1 (fr) | Procede de conditionnement genetique cible pour l'induction d'une transgenese ciblee somatique | |
| EP0751999A1 (fr) | Procede de therapie genique a l'aide de vecteurs d'adn exempts de gene d'antibioresistance | |
| DE10326189A1 (de) | Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe | |
| EP1631672B1 (fr) | Produit de synthese d'expression circulaire destine a des applications de therapie genique | |
| DE69730967T2 (de) | Human dnase ii | |
| DE60310708T2 (de) | In vivo stabilsierung von plasmiden | |
| KR102555172B1 (ko) | Gm-csf의 분비를 위한 유전자 구조물 및 이에 의해 형질전환된 항암 재조합 균주 | |
| EP1474519A2 (fr) | Micro-organisme a enveloppe | |
| WO2004108155A1 (fr) | Cellules utilisees comme vecteurs de bacteries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: ZENTARIS GMBH, 60314 FRANKFURT, DE |
|
| 8130 | Withdrawal |